Six-year change in high-sensitivity cardiac troponin T and risk of subsequent coronary heart disease, heart failure, and death

JAMA Cardiology

Volumn 1, Issue 5, 2016, Pages 519-528

  McEvoy, John W ^a,b   Chen, Yuan ^a   Ndumele, Chiadi E ^a,b   Solomon, Scott D ^c   Nambi, Vijay ^d,e,f   Ballantyne, Christie M ^e,f   Blumenthal, Roger S ^b   Coresh, Josef ^a   Selvin, Elizabeth ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

^f HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; TROPONIN T; BIOLOGICAL MARKER;

ADULT; AMINO TERMINAL SEQUENCE; ARTICLE; CARDIOVASCULAR RISK; CLINICAL OUTCOME; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEART EJECTION FRACTION; HEART FAILURE; HOSPITALIZATION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; RISK FACTOR; CORONARY ARTERY DISEASE; METABOLISM;

BIOMARKERS; CORONARY DISEASE; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TROPONIN T;

EID: 85007533973     PISSN: 23806583     EISSN: 23806591     Source Type: Journal    
DOI: 10.1001/jamacardio.2016.0765     Document Type: Article

References (35)

1. Thygesen K, Alpert JS, Jaffe AS, et al; Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction. Third universal definition of myocardial infarction. Circulation. 2012;126(16):2020-2035.
2. Apple FS. High-sensitivity cardiac troponin for screening large populations of healthy people: is there risk? Clin Chem. 2011;57(4):537-539.
3. Giannitsis E, Katus HA. Highly sensitive troponins knocking at the door of primary prevention. Eur Heart J. 2014;35(5):268-270.
4. Sherwood MW, Kristin Newby L. High-sensitivity troponin assays: evidence, indications, and reasonable use. J AmHeart Assoc. 2014;3(1): e000403.
5. Saunders JT, Nambi V, de Lemos JA, et al. Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis Risk in Communities Study. Circulation. 2011;123(13): 1367-1376.
6. de Lemos JA, Drazner MH, Omland T, et al. Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. JAMA. 2010;304(22): 2503-2512.
7. Eggers KM, Al-Shakarchi J, Berglund L, et al. High-sensitive cardiac troponin T and its relations to cardiovascular risk factors, morbidity, and mortality in elderly men. Am Heart J. 2013;166(3): 541-548.
8. Oluleye OW, Folsom AR, Nambi V, Lutsey PL, Ballantyne CM; ARIC Study Investigators. Troponin T, B-type natriuretic peptide, C-reactive protein, and cause-specific mortality. Ann Epidemiol. 2013; 23(2):66-73.
9. Wang TJ, Wollert KC, Larson MG, et al. Prognostic utility of novel biomarkers of cardiovascular stress: the Framingham Heart Study. Circulation. 2012;126(13):1596-1604.
10. de Filippi CR, de Lemos JA, Christenson RH, et al. Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults. JAMA. 2010;304(22):2494-2502.
11. Eggers KM, Venge P, Lindahl B, Lind L. Cardiac troponin I levels measured with a high-sensitive assay increase over time and are strong predictors of mortality in an elderly population. J AmColl Cardiol. 2013;61(18):1906-1913.
12. Selvin E, Lazo M, Chen Y, et al. Diabetes mellitus, prediabetes, and incidence of subclinical myocardial damage. Circulation. 2014;130(16): 1374-1382.
13. Masson S, Anand I, Favero C, et al; Valsartan Heart Failure Trial (Val-HeFT) and Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca-Heart Failure (GISSI-HF) Investigators. Serial measurement of cardiac troponin T using a highly sensitive assay in patients with chronic heart failure: data from 2 large randomized clinical trials. Circulation. 2012;125(2):280-288.
14. Omland T, Røsjø H, Giannitsis E, Agewall S. Troponins in heart failure. Clin Chim Acta. 2015;443: 78-84.
15. Borlaug BA, Paulus WJ. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur Heart J. 2011;32(6): 670-679.
16. The ARIC Investigators. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. Am J Epidemiol. 1989;129(4):687-702.
17. Agarwal SK, Avery CL, Ballantyne CM, et al. Sources of variability in measurements of cardiac troponin T in a community-based sample: the atherosclerosis risk in communities study. Clin Chem. 2011;57(6):891-897.
18. Giannitsis E, Kurz K, Hallermayer K, Jarausch J, Jaffe AS, Katus HA. Analytical validation of a high-sensitivity cardiac troponin T assay. Clin Chem. 2010;56(2):254-261.
19. Parrinello CM, Grams ME, Couper D, et al. Recalibration of blood analytes over 25 years in the atherosclerosis risk in communities study: impact of recalibration on chronic kidney disease prevalence and incidence. Clin Chem. 2015;61(7):938-947.
20. Casale PN, Devereux RB, Alonso DR, Campo E, Kligfield P. Improved sex-specific criteria of left ventricular hypertrophy for clinical and computer interpretation of electrocardiograms: validation with autopsy findings. Circulation. 1987;75(3): 565-572.
21. Levey AS, Stevens LA, Schmid CH, et al; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009; 150(9):604-612.
22. White AD, Folsom AR, Chambless LE, et al. Community surveillance of coronary heart disease in the Atherosclerosis Risk in Communities (ARIC) Study: methods and initial two years' experience. J Clin Epidemiol. 1996;49(2):223-233.
23. Rosamond WD, Chang PP, Baggett C, et al. Classification of heart failure in the Atherosclerosis Risk in Communities (ARIC) Study: a comparison of diagnostic criteria. Circ Heart Fail. 2012;5(2):152-159.
24. Lindenfeld J, Albert NM, Boehmer JP, et al; Heart Failure Society of America. HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail. 2010;16(6): e1-e194.
25. Kelly JP, Mentz RJ, Mebazaa A, et al. Patient selection in heart failure with preserved ejection fraction clinical trials. J AmColl Cardiol. 2015;65(16): 1668-1682.
26. Wu AH, Lu QA, Todd J, Moecks J, Wians F. Short- and long-term biological variation in cardiac troponin I measured with a high-sensitivity assay: implications for clinical practice. Clin Chem. 2009; 55(1):52-58.
27. Everett BM, Brooks MM, Vlachos HE, Chaitman BR, Frye RL, Bhatt DL; BARI 2D Study Group. Troponin and Cardiac Events in Stable Ischemic Heart Disease and Diabetes. N Engl J Med. 2015;373(7):610-620.
28. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15 (4):361-387.
29. Pencina MJ, D'Agostino RB Sr, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med. 2011;30(1):11-21.
30. Glick D, DeFilippi CR, Christenson R, Gottdiener JS, Seliger SL. Long-term trajectory of two unique cardiac biomarkers and subsequent left ventricular structural pathology and risk of incident heart failure in community-dwelling older adults at low baseline risk. JACC Heart Fail. 2013;1(4):353-360.
31. White HD, Tonkin A, Simes J, et al; LIPID Study Investigators. Association of contemporary sensitive troponin I levels at baseline and change at 1 year with long-term coronary events following myocardial infarction or unstable angina: results from the LIPID Study (Long-Term Intervention With Pravastatin in Ischaemic Disease). J AmColl Cardiol. 2014;63(4):345-354.
32. Seliger SL, de Lemos J, Neeland IJ, et al. Older adults, "malignant" left ventricular hypertrophy, and associated cardiac-specific biomarker phenotypes to identify the differential risk of new-onset reduced versus preserved ejection fraction heart failure: CHS (Cardiovascular Health Study). JACC Heart Fail. 2015;3(6):445-455.
33. Ledwidge M, Gallagher J, Conlon C, et al. Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial. JAMA. 2013;310(1):66-74.
34. O'Meara E, de Denus S, Rouleau JL, Desai A. Circulating biomarkers in patients with heart failure and preserved ejection fraction. Curr Heart Fail Rep. 2013;10(4):350-358.
35. Packer M, McMurray JJ, Desai AS, et al; PARADIGM-HF Investigators and Coordinators. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation. 2015;131(1):54-61.